2011
Sluggish stent sales at Boston Scientific continue to afflict Angiotech
The best thing you can say about Angiotech Pharmaceutical Inc.’s (NSDQ:ANPI) fourth quarter is that it’s over.
The zombie deal that won’t die: Smith & Nephew
No matter how many times Smith & Nephew (NYSE:SNN) says it’s not talking merger, somebody else says it is.
Change is in the air at Haemonetics as Nutter steps away
Brad Nutter, the turnaround artist who helped pump new life into Haemonetics Corp. (NYSE:HAE) as CEO and later chairman of the board, said he will retire from the company’s board of directors effective November 1, 2010.
The move, announced on Monday in conjunction with the company’s first quarter earnings release, completes the transition to current CEO Brian Concannon, who moved into the corner office in April 2009.
Medtronic foresees increased revenue growth for fiscal 2011
Device maker Medtronic Inc. (NYSE:MDT) reaffirmed its financial projections for fiscal 2011, with revenue growth expected between five and eight percent.
The company expects diluted earnings per share between $3.45 and $3.55 for the full year, according to a statement from Medtronic. The consensus analysts’ estimate is earnings per share of $3.51.